Skip to content
10-Q

Quarterly Report

TriSalus Life Sciences, Inc. TLSI TLSIW

0001628280-26-034100

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 61.42M sh
Shares Diluted Q1 2026 · Mar 31, 2026 52.31M sh
Shares Diluted Q1 2026 · Mar 31, 2025 28.53M sh
Capex Q1 2026 · Mar 31, 2026 $141K
Capex Q1 2026 · Mar 31, 2025 $754K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$6.48M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$4.5M
Long Term Debt Q1 2026 · Mar 31, 2026 $33.08M
Long Term Debt Q1 2026 · Dec 31, 2025 $33.05M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $56.55M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $20.44M
Stockholders Equity Q1 2026 · Mar 31, 2026 $12.81M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$33.86M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$34.37M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$25.89M
Current Liabilities Q1 2026 · Mar 31, 2026 $11.79M
Current Liabilities Q1 2026 · Dec 31, 2025 $11.5M
Total Liabilities Q1 2026 · Mar 31, 2026 $58.17M
Total Liabilities Q1 2026 · Dec 31, 2025 $69.19M
Current Assets Q1 2026 · Mar 31, 2026 $68.14M
Current Assets Q1 2026 · Dec 31, 2025 $32.24M
Total Assets Q1 2026 · Mar 31, 2026 $70.98M
Total Assets Q1 2026 · Dec 31, 2025 $35.33M
Eps Diluted Q1 2026 · Mar 31, 2026 $0.03
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.39
Eps Basic Q1 2026 · Mar 31, 2026 $0.03
Eps Basic Q1 2026 · Mar 31, 2025 −$0.39
Sga Expense Q1 2026 · Mar 31, 2026 $5.45M
Sga Expense restated Q1 2026 · Mar 31, 2025 $5.25M
Rd Expense Q1 2026 · Mar 31, 2026 $3.22M
Rd Expense restated Q1 2026 · Mar 31, 2025 $3.02M
Net Income Q1 2026 · Mar 31, 2026 $1.54M
Net Income Q1 2026 · Mar 31, 2025 −$10.38M
Operating Income Q1 2026 · Mar 31, 2026 −$8.41M
Operating Income Q1 2026 · Mar 31, 2025 −$7.33M
Gross Profit Q1 2026 · Mar 31, 2026 $7.67M
Gross Profit Q1 2026 · Mar 31, 2025 $7.67M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $1.23M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $1.5M
Revenue Q1 2026 · Mar 31, 2026 $8.9M
Revenue Q1 2026 · Mar 31, 2025 $9.17M